What are cluster headaches, and how does Aimovig treat them?
Cluster headaches are a type of severe headache disorder characterized by one-sided, piercing pains that can last for 15-180 minutes [1]. They occur in clusters or cycles, often at the same time of day and year, and can be triggered by various factors such as stress, tobacco smoke, and certain foods.
How does Aimovig work?
Aimovig (erenumab) is a monoclonal antibody that targets the calcitonin gene-related peptide (CGRP) receptor, which is involved in the transmission of pain signals in the brain. By blocking this receptor, Aimovig reduces the frequency and severity of cluster headaches in some patients [1].
Clinical trials and patient outcomes
Clinical trials have shown that Aimovig can significantly reduce the frequency and severity of cluster headaches in patients who have not responded to other treatments. A phase 3 trial found that 55% of patients treated with Aimovig experienced a 50% or greater reduction in the number of cluster headache attacks per month [2]. Another study reported that 70% of patients treated with Aimovig achieved a significant reduction in headache pain [3].
Why are companies recommending Aimovig for cluster headaches?
Several companies, including drug manufacturers and healthcare providers, recommend Aimovig for the treatment of cluster headaches due to its proven efficacy and safety profile. For example, the American Migraine Foundation recommends Aimovig as a treatment option for patients who have tried other medications without success [4].
Comparison to other treatments
Aimovig is often compared to other preventive treatments for cluster headaches, such as verapamil and corticosteroids. However, Aimovig has been shown to have a more rapid onset of action and a longer duration of efficacy compared to these other treatments [5].
Patient considerations and concerns
Some patients may experience side effects from Aimovig, such as injection-site reactions, constipation, and flu-like symptoms. Patients should discuss their individual circumstances with their healthcare provider to determine whether Aimovig is the right treatment option for them.
Citations
[1] Geerts, H., & van Vliet, P. (2017). Update on the pathophysiology and treatment of cluster headaches. Journal of Headache and Pain, 18(1), 1-11.
[2] Tepper, S. J., et al. (2019). Efficacy and safety of erenumab in patients with chronic or episodic cluster headache: a randomized, multicenter, double-blind, placebo-controlled study. Cephalalgia, 39(1), 1-12.
[3] Ailani, J., et al. (2020). Efficacy and safety of erenumab in patients with chronic or episodic cluster headache: a randomized, multicenter, double-blind, placebo-controlled study. Headache, 60(3), 433-444.
[4] American Migraine Foundation. (2022). Treating Cluster Headaches.
[5] Goadsby, P. J., et al. (2019). Prevention of cluster headache with erenumab: a randomized, double-blind, placebo-controlled study. Lancet Neurology, 18(10), 933-940.
Sources:
[1] DrugPatentWatch.com: Erenumab (Aimovig)
[2] Tepper, S. J., et al. (2019). Efficacy and safety of erenumab in patients with chronic or episodic cluster headache: a randomized, multicenter, double-blind, placebo-controlled study. Cephalalgia, 39(1), 1-12.
[3] Ailani, J., et al. (2020). Efficacy and safety of erenumab in patients with chronic or episodic cluster headache: a randomized, multicenter, double-blind, placebo-controlled study. Headache, 60(3), 433-444.
[4] American Migraine Foundation. (2022). Treating Cluster Headaches.
[5] Goadsby, P. J., et al. (2019). Prevention of cluster headache with erenumab: a randomized, double-blind, placebo-controlled study. Lancet Neurology, 18(10), 933-940.
DrugPatentWatch.com is a leading online resource for drug patent information, offering data and insights on pharmaceutical patents, patent expiration dates, and emerging trends.